Hartmann, Viaflo

Hartmann Viaflo is an intravenous electrolyte solution that contains potassium chloride, sodium chloride, calcium chloride dihydrate, and sodium lactate. It is supplied as a sterile liquid for infusion and is used in clinical settings to provide fluid and electrolyte replacement. The product is manufactured for the European market and is available by prescription only. Its formulation is designed to help correct electrolyte imbalances and support hydration.

Hartmann Viaflo is indicated for clinical situations that require rapid restoration of fluid volume and electrolyte balance. It is commonly employed in hospitals for the following purposes: - Replacement of potassium in patients with hypokalemia. - Correction of low sodium levels (hyponatremia) during fluid therapy. - Provision of calcium and chloride ions in patients with electrolyte depletion. - Support of fluid resuscitation in postoperative or trauma patients. - Maintenance of acid‑base balance through sodium lactate conversion to bicarbonate. - Administration during renal replacement therapy to help manage electrolyte shifts.

Intravenous administration of Hartmann Viaflo may be associated with a range of adverse reactions. The frequency and severity of these events vary among patients.

Common: - Mild infusion site irritation or erythema. - Transient nausea or vomiting. - Slight increase in serum potassium leading to mild hyperkalemia. - Temporary metabolic alkalosis due to sodium lactate metabolism. - Mild headache or dizziness during infusion. - Transient increase in blood pressure due to fluid volume expansion.

Serious: - Severe hyperkalemia causing cardiac arrhythmias. - Rapid shifts in serum sodium resulting in osmotic demyelination. - Allergic reactions such as urticaria, bronchospasm, or anaphylaxis. - Severe metabolic acidosis if lactate accumulation occurs in patients with liver dysfunction.

When using Hartmann Viaflo, clinicians should evaluate patient-specific factors to minimize risk. Particular attention is required for conditions that affect electrolyte balance or fluid status. - Assess renal function before and during therapy. - Monitor serum potassium, sodium, and calcium levels regularly. - Adjust infusion rate in patients with heart failure or fluid overload. - Use cautiously in individuals with metabolic acidosis or alkalosis. - Avoid rapid administration in neonates and small children. - Review concomitant potassium‑sparing medications for possible accumulation. - Consider lactate metabolism capacity in severe liver disease.

Hartmann Viaflo may interact with other medications that influence electrolyte concentrations or fluid balance. Identifying potential interactions helps prevent adverse events during intravenous therapy.

Avoid: - Concurrent high‑dose potassium supplements or potassium‑sparing diuretics. - Co‑administration with hypertonic saline solutions. - Simultaneous infusion of calcium‑binding agents such as citrate. - Infusion together with other intravenous electrolyte solutions without adjusting total electrolyte load.

Use with caution: - Loop or thiazide diuretics that may cause rapid electrolyte shifts. - ACE inhibitors or ARBs that affect potassium homeostasis. - Blood products containing citrate, which can alter calcium levels. - Patients receiving insulin therapy, as insulin drives potassium into cells and may exacerbate hypokalemia.